Tango Therapeutics Climbs 36% to $16.97 on Stifel Buy Rating
Shares of Tango Therapeutics rallied to $16.97 and closed up 36.3% at $16.83 after Stifel reiterated its buy rating with a $15 target. Last year, the company narrowed its net loss by 22% to $101.6 million on 48.3% revenue growth to $62.4 million and signed a vopimetostat collaboration with Erasca.
1. Stock Rallies to Record High
Shares of Tango Therapeutics jumped to an intra-day peak of $16.97 and closed up 36.3% at $16.83 after Stifel reiterated its buy recommendation and $15 price target.
2. Annual Earnings Improvement
In 2025, Tango narrowed its net loss by 22% to $101.6 million and boosted revenues by 48.3% to $62.4 million, though Q4 saw a $38.7 million loss and no revenue versus $5.4 million a year earlier.
3. Expanding Clinical Pipeline
The company plans multiple 2026 trials testing vopimetostat in combination therapies and entered a collaboration and supply agreement with Erasca to study vopimetostat plus ERAS-0015 for pancreatic cancer.